Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
Editta Baldini, Diana Giannarelli(Agostino Gemelli University Polyclinic), Valeria Stati(Istituti di Ricovero e Cura a Carattere Scientifico), Gianpiero Fasola, D. Turci(Azienda Ospedaliera San Camillo-Forlanini), Biagio Ricciuti(Harvard University), Giacomo Cartenì(Ospedale Antonio Cardarelli), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Giovanni Luca Ceresoli(Humanitas Gavazzeni), Carmelo Tibaldi(Azienda Ospedaliero-Universitaria Careggi), Giampiero Romano(Ospedale Vito Fazzi), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Barbara Melotti(Roche (Switzerland)), Francesco Verderame(Ospedale Vincenzo Cervello), Luisa Fioretto(Ospedale SS. Annunziata), Enrico Ricevuto(University of L'Aquila), Enrico Cortesi(Sapienza University of Rome), Alfonso Illiano, Diego Signorelli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Alice Lunghi(Azienda Ospedaliero-Universitaria Careggi), Vieri Scotti(University of Florence)
Cited by 42
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k